Back to search results

CBIT for Tourette Syndrome and Persistent Tic Disorder

This study is looking at how well a treatment called Comprehensive Behavioral Intervention for Tics (CBIT) works for young people with Tourette Syndrome or Persistent Tic Disorder. CBIT is a manualized treatment that helps you learn skills to manage tics, including a technique called "competing response training" where you learn to do a different action to stop a tic. The study wants to understand what predicts who responds best to CBIT and which parts of the treatment are most effective. You can join if you are between 10 and 17 years old and have had chronic tics for at least one year. The main goal is to see how much your tics improve, measured by a specific tic severity scale, after 27 weeks. The current status of this study is unclear.

Study design
This is an interventional study planning to enroll 100 participants. It is a single-arm study, meaning all participants will receive the CBIT intervention.
What's involved
You will receive 8 CBIT sessions delivered weekly over 10 weeks. All sessions will be video recorded.
Compensation
Not stated in the trial record.
Follow-up
Your tic severity will be measured at 27 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06194305

Multimodal Profiling of Response to Pediatric Comprehensive Behavioral Intervention for Tics

Recruiting
PHASE2Ages 10–17InterventionalHealth services
University of Minnesota
~100 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:CBIT

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in the Total Tic Score on the Yale Global Tic Severity Scale (YGTSS).
Measured over 27 weeks

Conditions

Tourette Syndrome
Persistent Tic Disorder

Explore related trials

Persistent Tic DisorderTourette Syndrome

Where it's being run

2 sites across 2 states
California1
Minnesota1

Study leadership

  • Christine Conelea, PhD, LP · PRINCIPAL_INVESTIGATOR · University of Minnesota
  • Deanna Greene, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Diego
  • Sonya Wang, MD · PRINCIPAL_INVESTIGATOR · University of Minnesota

Who to contact

Sonya Wang, MD
[email protected]
612-301-1454
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 10-17 years at time of enrollment.
Current chronic motor and/or vocal tics, defined as tics for at least 1 year without a tic-free period of more than 3 consecutive months. Tics must not be due to a medical condition or the direct physiological effects of a substance.
At least moderate tic severity, defined as a Yale Global Tic Severity Scale total score ≥14 (≥9 for those with motor or vocal tics only).
Full scale IQ greater than 70.
Child participant required to have English fluency to ensure comprehension of study measures and instructions.
To increase external validity of findings, we will include participants taking psychotropic medications that have been stable for 4 weeks and expect to remain stable for the study period. Individuals receiving non-tic related psychotherapy involving procedures that overlap with CBIT can be eligible to participate if they refrain from receiving treatment once enrolled through the post-treatment assessment. All concurrent treatments will be monitored.

Exclusion

Inability to undergo MRI (e.g., metal in body, claustrophobia, orthodontia) and/or EEG.
Active suicidality Previous diagnosis of psychosis, cognitive disability, or structural brain disease that in the investigator opinion would impede participation.
History of seizure disorder
Active substance abuse or dependence.
Presence of another psychiatric or medical condition requiring immediate treatment and/or for which delay of treatment to focus on tics would be clinically inappropriate. Participants will not be excluded for comorbidities that commonly occur with TS (e.g., ADHD, OCD, anxiety) provided that this criterion is met, as only 10-15% of patients with TS have no comorbidities.
Concurrent psychotherapy focused on tics and/or involving procedures that overlap with CBIT (e.g., habit reversal therapy, exposure therapy targeting repetitive behaviors).
Psychotropic medication changes in the past 4 weeks and/or plans to change medication during the study period through post-treatment assessment.
≥ 4 previous sessions of CBIT.

What this trial measures

  • Change in the Total Tic Score on the Yale Global Tic Severity Scale (YGTSS).27 weeks

    The YGTSS is a clinician-rated measure that will be scored by a study Independent Evaluator. For each participant, the severity of tics over the past 1 week will be measured using the sing a data-dYGTSS Total Tic Score, which ranges from ranges from 0-50. Outcome will be reported as change from baseline to post-treatment, change from baseline to 1-month post-treatment, and change from post-treatment to 1-month post-treatment.